A network pharmacology and bioinformatics exploration of the possible molecular mechanisms of Fuzheng Xiaoliu Granule for the treatment of hepatocellular carcinoma
Background and aim: Hepatocellular carcinoma (HCC) is one of the ten most common malignant tumors in the world, and it is a major problem in the world. Traditional Chinese medicine (TCM) has many advantages in the prevention and treatment of HCC, but its complicated mechanism of action is difficult to clarify, which limits its research and development. The continuous development of bioinformation technology provides new methods and opportunities for the research of traditional Chinese medicine. This study uses modern network pharmacology and bioinformatic methods to explore the possible molecular mechanism of the Chinese herbal compound Fuzheng Xiaoliu Granule (FZXLG) to treat HCC, to provide a theoretical basis for their clinical application and basic research, to promote the modernization of traditional Chinese medicine and to promote its worldwide application.
Methods: The active ingredients of FZXLG were collected and screened through TCMSP, BATMAN-TCM, and other databases. The targets of FZXLG were predicted by PubChem and SwissTargetPrediction; HCC disease-related targets were obtained by GeneCards, OMIM, and other disease databases, and the potential gene targets of FZXLG for HCC treatment were screened. The "Prescription-TCMs-Ingredients-Targets" network for FZXLG for the treatment of HCC was constructed, along with the screening of core effective components. The differentially expressed genes(DEGs) of HCC tumor and non-tumor adjacent tissues combined with clinical data in the TCGA database were analyzed to obtain the prognostic genes of HCC. Then, FZXLG genes affecting HCC prognosis were screened, and further screening the core target genes. The correlation between core gene expression with prognosis, immune cell infiltration, and immunohistochemical changes in HCC patients was studied. KEGG enrichment analysis and GO enrichment analysis of the FZXLG genes affecting HCC prognosis were performed by using DAVID database. AutoDockTools software was then used for molecular docking verification.
Results: The ten core effective ingredients of FZXLG for HCC treatment included multiple flavonoids ingredients such as quercetin, luteolin, and formononetin. 11 core targets of FZXLG affecting the prognosis of HCC were screened, among which ESR1 and CAT were favorable prognostic factors, while EGF, MMP9, CCNA2, CCNB1, CDK1, CHEK1, and E2F1 were adverse prognostic factors. MMP9 and EGF were positively correlated with six TIIC subsets. The different expression levels of CAT, PLG, AR, MMP9, CCNA2, CCNB1, CDK1, and E2F1 were correlated with the immunohistochemical staining changes in normal liver and liver cancer. KEGG pathway enrichment analysis yielded 33 pathways including cell cycle, p53, hepatitis B, and other signaling pathways. Molecular docking verified that the main core components had good binding to the protective prognostic core targets ESR1 and CAT.
Conclusions: FZXLG may treat HCC through multiple ingredients, multiple targets, and multiple pathways, affecting the prognosis, immune microenvironment, and immunohistochemical changes of HCC.
Relevance for patients: FZXLG is a Chinese herbal compound for the treatment of hepatocellular carcinoma, with significant clinical efficacy. However, the mechanism of action is unclear and lacks theoretical support, which limits its popularization application. This study preliminarily revealed its molecular mechanism, providing a theoretical basis for its clinical application, which can better guide its clinical popularization application, and also provide a new strategy for the treatment of HCC.
[1] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global Cancer Statistics 2018: Globocan Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2018;68:394-424.
[2] Zhong CJ, Wang X. Study on the Treatment and Risk Factors of Primary Liver Cancer with Integrated Traditional Chinese and Western Medicine. J Jinzhou Med Univ 2019;40:106-8.
[3] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: Globocan Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021;71:209-49.
[4] Huang ZS, Chou YY. The Research Status of Traditional Chinese Medicine in the Treatment of Primary Liver Cancer. Lishizhen Med Mater Med Res 2012;23:2851-3.
[5] Jiang YL, Pan MQ, Huang G. Consensus on Diagnosis and Treatment of Primary Liver Cancer with Integrated Traditional Chinese and Western Medicine. Guiding J Tradit Chin Med Pharm 2021;27:101-7.
[6] Chen XQ, Chen XJ, Ji AY, Zhang CL, Wang XT. Seventyfive Cases of Primary Liver Cancer Treated with Granule for Strengthening the Body Resistance and Removing Tumor in Combination with Minimally Invasive Treatment. Henan Tradit Chin Med 2019;39:576-8.
[7] Chen XQ, Zhang PG, Chen XR, Ji AY, Lv Z, Zhao YX, et al. Effects of Fuzheng Xiaoliu Granule on the Expression of VEGF and HIF-1α in Serum of Primary Hepatocellular Carcinoma and its Clinical Significance. Mod Tradit Chin Med Mater Med World Sci Technol 2020;22:3629-35.
[8] Chen XQ, Chen XR, Zhang PG, Ji AY, Lv Z, Zhao YX, et al. Effects of Fuzheng Xiaoliu Granules on Serum TGF-β1, CCL22 Level and Quality of Life in Patients with Primary Hepatic Cancer. China J Tradit Chin Med Pharm 2021;36:4386-90.
[9] Chen XQ, Chen XJ, Wang XT, Zhang CL, Ji AY. Effect of Fuzheng Xiaoliu Granule Drug-containing Serum on Proliferation and Apoptosis-related Proteins of Hepatocarcinoma HepG2 cells in vitro. Acta Chin Med 2018;33:701-5.
[10] Niu M, Zhang SQ, Zhang B, Yang K, Li S. Interpretation of Network Pharmacology Evaluation Method Guidance. Chin Tradit Herb Drugs 2021;52:4119-29.
[11] Huang J, Cheung F, Tan HY, Hong M, Wang N, Yang J, et al. Identification of the Active Compounds and Significant Pathways of Yinchenhao Decoction Based on Network Pharmacology. Mol Med Rep 2017;16:4583-92.
[12] Daina A, Michielin O, Zoete V. SwissTargetPrediction: Updated Data and New Features for Efficient Prediction of Protein Targets of Small Molecules. Nucleic Acids Res 2019;47:W357-64.
[13] Yang WQ, Huang ZH, Yuan HS, Geng YF, Zang CC, Jin RQ, et al. Study on the Mechanism of Longju Qinggan capsule in the Treatment of Essential Hypertension Based on Network Pharmacology. Lishizhen Med Mater Med Res 2021;32:1261-6.
[14] Zhang T, Li N, Song XF, Zhu T. Anti-liver Cancer Mechanism of Hypericin based on Network Pharmacology and Molecular Docking Enhanced Publishing. Chin J Exp Tradit Med Formulae 2022;28:183-91.
[15] Wang L, Zhao Q, Chen XQ, Zhang CL, Wang XT, Chen XJ. Effect of Fuzheng Xiaoliu Granule on Nude Mice Bearing Hepatoma HepG2 Tumor. Chin J Integr Tradit West Med Liver Dis 2020;30:231-3, 289.
[16] Wei YF, Liu SS, Jin LJ, Chen WJ, Lin YN, Liu H. Research Progress on Anti-tumor Effects of Flavonoid Monomers from Traditional Chinese Medicine Based on PI3K/AKT Signaling Pathway. Chin Arch Tradit Chin Med 2021;39:6- 10, 259.
[17] Baby J, Devan AR, Kumar AR, Gorantla JN, Nair B, Aishwarya TS, et al. Cogent Role of Flavonoids as Key Orchestrators of Chemoprevention of Hepatocellular Carcinoma: A Review. J Food Biochem 2021;45:e13761.
[18] Zhou J, Li L, Fang L, Xie H, Yao W, Zhou X, et al. Quercetin Reduces Cyclin D1 Activity and Induces G1 Phase Arrest in HepG2 Cells. Oncol Lett 2016;12:516-22.
[19] Lu J, Wang Z, Li S, Xin Q, Yuan M, Li H, et al. Quercetin Inhibits the Migration and Invasion of HCCLM3 Cells by Suppressing the Expression of P-Akt1, Matrix Metalloproteinase (MMP) MMP-2, and MMP-9. Med Sci Monit 2018;24:2583-9.
[20] Chen J, Deng M, Zhou H, Cheng DM. Luteolin Suppressed PKM2 and Promoted Autophagy for Inducing the Apoptosis of Hepatocellular Carcinoma Cells. Chin J Hosp Pharm 2021;41:1103-8.
[21] Arul D, Subramanian P. Naringenin (Citrus Flavonone) Induces Growth Inhibition, Cell Cycle Arrest and Apoptosis in Human Hepatocellular Carcinoma Cells. Pathol Oncol Res 2013;19:763-70.
[22] Gao X, Yanan J, Santhanam RK, Wang Y, Lu Y, Zhang M, et al. Garlic Flavonoids Alleviate H2 O2 Induced Oxidative Damage in L02 Cells and Induced Apoptosis in HepG2 Cells by Bcl-2/Caspase Pathway. J Food Sci 2021;86:366-75.
[23] Hong Y, Ye M, Luo J, Wang C, Liu J, Ren C, et al. Effect of Oncogene Yap1 Silencing Combined with Tanshinone IIA on Huh-7 Hepatoma Cells. J Clin Hepatol 2021;37:348-53.
[24] Jiao W, Jiao W, Zhang J. Formononetin Affects the Pathogenesis of Liver Cancer by Inhibiting the COX-2/ cyclin D1 Axis. Chin J Cancer Biother 2021;6:877-84.
[25] Kur P, Kolasa-Wołosiuk A, Misiakiewicz-Has K, Wiszniewska B. Sex Hormone-dependent Physiology and Diseases of Liver. Int J Environ Res Public Health 2020;17:2620.
[26] Bhat M, Pasini E, Pastrello C, Angeli M, Baciu C, Abovsky M, et al. Estrogen Receptor 1 Inhibition of Wnt/β-catenin Signaling Contributes to Sex Differences in Hepatocarcinogenesis. Front Oncol 2021;11:777834.
[27] Li X, Yu H, Huang Y, Chen Y, Wang J, Xu L, et al. Preparation of Microspheres Encapsulating Sorafenib and Catalase and their Application in Rabbit VX2 Liver Tumor. Biomed Pharmacother 2020;129:110512.
[28] Scheau C, Badarau IA, Costache R, Caruntu C, Mihai GL, Didilescu AC, et al. The Role of Matrix Metalloproteinases in the Epithelial-mesenchymal Transition of Hepatocellular Carcinoma. Anal Cell Pathol (Amst) 2019;2019:9423907.
[29] Liu T, Shi Q, Yang L, Wang S, Song H, Wang Z, et al. Long non-coding RNAs HERH-1 and HERH-4 Facilitate Cyclin A2 Expression and Accelerate Cell Cycle Progression in Advanced Hepatocellular Carcinoma. BMC Cancer 2021;21:957.
[30] Li J, Xia T, Cao J, He D, Chen Z, Liang B, et al. RP11-295G20.2 Facilitates Hepatocellular Carcinoma Progression via the mir-6884-3p/ccnb1 Pathway. Aging (Albany NY) 2020;12:14918-32.
[31] Hao L, Li S, Peng Q, Guo Y, Ji J, Zhang Z, et al. Antimalarial Drug Dihydroartemisinin Downregulates the Expression Levels of CDK1 and CCNB1 in Liver Cancer. Oncol Lett 2021;22:653.
[32] Wu CX, Wang XQ, Chok SH, Man K, Tsang SH, Chan AC, et al. Blocking CDK1/PDK1/β-catenin Signaling by cdk1 Inhibitor ro3306 Increased the Efficacy of Sorafenib Treatment by Targeting Cancer Stem Cells in a Preclinical Model of Hepatocellular Carcinoma. Theranostics 2018;8:3737-50.
[33] Gong D, Feng PC, Ke XF, Kuang HL, Pan LL, Ye Q, et al. Silencing Long Non-coding RNA LINC01224 Inhibits Hepatocellular Carcinoma Progression via Microrna-330- 5P-induced Inhibition of CHEK1. Mol Ther Nucleic Acids 2020;19:482-97.
[34] Shen C, Li J, Chang S, Che G. Advancement of E2F1 in Common Tumors. Zhongguo Fei Ai Za Zhi 2020;23:921-6.
[35] Li SY, Zhu Y, Li RN, Huang JH, You K, Yuan YF, et al. LncRNA Lnc-APUE is Repressed by HNF4α and Promotes G1/S Phase Transition and Tumor Growth by Regulating MiR-20b/E2F1 axis. Adv Sci (Weinh) 2021;8:2003094.
[36] Sabbah DA, Hajjo R, Sweidan K. Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors. Curr Top Med Chem 2020;20:815-34.
[37] Wang T, Wang RH. Research Progress of Epidermal Growth Factor Receptor in Pathogenesis and Targeted Therapy of Hepatocellular Carcinoma. Chin J Surg Oncol 2017;9:327-30.
[38] Yang LH, Hu KW, Wang JX. Mechanism of Therapeutic Methods of Activating Blood, Resolving Phlegm, and Removing Toxins in Liver Cancer Based on Immune Microenvironment. Chin J Exp Tradit Med Formulae 2022;28:172-8.
[39] Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS, et al. Timer: A Web Server for Comprehensive Analysis of Tumorinfiltrating Immune Cells. Cancer Res 2017;77:e108-10.
[40] Khan H, Reale M, Ullah H, Sureda A, Tejada S, Wang Y, et al. Anti-cancer Effects of Polyphenols via Targeting p53 Signaling Pathway: Updates and Future Directions. Biotechnol Adv 2020;38:107385.
[41] Yu M, Xu W, Jie Y, Pang J, Huang S, Cao J, et al. Identification and Validation of Three Core Genes in p53 Signaling Pathway in Hepatitis b Virus-related Hepatocellular Carcinoma. World J Surg Oncol 2021;19:66.
[42] McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of Hepatocellular Carcinoma. Hepatology 2021;73 Suppl 1:4-13.